COVID-19 infections present a significant risk of secondary infection, as seen in emerging reports of a link between COVID-19 and fungal co-infections such as aspergillosis.
Fungal co-infections are a severe threat to patients already weakened by COVID-19 infection. These fungal co-infections need to be identified rapidly for antifungal therapy to be successful.
Invasive fungal infections can be challenging to identify. Bringing fungal diagnostics in-house can lead to a significant reduction in result reporting turnaround time. BioConnections is introducing a range of products to UK clinical laboratories for the rapid detection of various biomarkers used to
screen for fungal diseases, and, when combined with the Merlin Micronaut antifungal susceptibility testing system, enables rapid targeted patient care.
More information on these new products is available from BioConnections through a virtual presentation.